The MPTP story: MAO activates tetrahydropyridine derivatives to toxins causing parkinsonism.
Maret
G
G
Institut de Chimie Thérapeutique, Ecole de Pharmacie Université de Lausanne, Switzerland.
Testa
B
B
Jenner
P
P
el Tayar
N
N
Carrupt
P A
PA
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / Q000009:adverse effects*; D055598:Chemical Phenomena; D002621:Chemistry; D006801:Humans; D008995:Monoamine Oxidase / Q000378:metabolism*; D009498:Neurotoxins / Q000378:metabolism; D010302:Parkinson Disease, Secondary / Q000139:chemically induced*
D009498:Neurotoxins; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D008995:Monoamine Oxidase